FDA Brief

Warning letters Food

FDA warning letter to

Top Health Manufacturing, LLC

MediumIssued Jun 3, 2024Posted Nov 5, 2024Division of Human and Animal Food Operations West IV

Top Health Manufacturing's dietary supplements violated manufacturing and labeling rules, FDA says.

What happened

FDA inspected the dietary supplement facility in Spanish Fork, Utah, on October 12-13, 16, 18, and 20, 2023, and reviewed product labels collected during the inspection. FDA found violations of current good manufacturing practice (CGMP), the rules for how dietary supplements are made, and labeling violations.

What FDA found

  1. The quality control unit did not follow the company's written quality procedures: master and batch records were not approved or reviewed, internal audits were not done since 2022, and calibration logs and lab results were not reviewed.

    21 CFR 111.103
  2. The company did not set identity specifications, or purity and strength specifications, for components such as marshmallow root powder, juniper berry powder, and yarrow herb/flower powder.

    21 CFR 111.70(b)(1) and (b)(2)
  3. The company did not set finished-product specifications for identity, purity, strength, and composition for Grandma's Herbs Kidney and the redacted second product.

    21 CFR 111.70(e)
  4. The master manufacturing records for Grandma's Herbs Kidney and the redacted second product lacked required elements, including yield limits, a label or label location, and detailed manufacturing instructions.

    21 CFR 111.210
  5. The batch production records lacked required information, including equipment cleaning dates and times, percentage yield, dates each step was performed, and packaging documentation.

    21 CFR 111.255(b) and 111.260
  6. Labeling was false or incomplete: Grandma's Herbs Kidney did not identify plant parts, a product label listed candelilla wax though the batch record showed it was not added, and nutrition information did not meet format rules.

    section 403 of the Act [21 U.S.C. ยง 343]; 21 CFR 101.4(h)(1), 101.36, and 101.9

What FDA wants

FDA asks the company to respond in writing within 15 working days with the specific steps taken to correct the violations and prevent recurrence, including documentation such as revised procedures and test results. If corrective actions cannot be completed in that time, the company must explain the delay and state when it will finish.

Who should pay attention

  • dietary supplement contract manufacturers
  • brands that buy finished supplements from this facility
  • retailers selling Grandma's Herbs Kidney

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk